Advantages
- Commercial Differentiation: A groundbreaking model enabling non-invasive, longitudinal imaging in the same individual, replacing conventional euthanasia-dependent histopathology.
- Superior Penetration & Quantification: Overcomes conventional fluorescent limitations to achieve real-time live imaging of deep organs and precise spermatogenic cell quantification.
- Dual In Vivo / In Vitro Expansion: Offers high commercial potential ranging from live imaging models to primary cells and assay kits for high-throughput screening.
Current Stage and Key Data
Evaluation model mouse establishment fully completed and Proof of Concept (PoC) achieved.
- High Signal Reproducibility and Quantitative Accuracy: Demonstration of an exceptionally high positive correlation between primary spermatogenic cell numbers and bioluminescence intensity
- Long-term In Vivo Signal Stability: Maintenance of stable bioluminescence across aging individuals (over 44 weeks) without background signal fluctuation
- Quantitative Discrimination of Dose-Dependent Toxicities: Quantitative detection of reversible vs. irreversible testicular damage under local X-ray irradiation, and validated quantitative responsiveness to anticancer drugs (Trichostatin A) and endocrine disruptors (Bisphenol A).
Partnaring Model
Mouse model deposition, colony maintenance/safekeeping agreements, licensing for breeding and sales, frozen embryo/live animal supply partnerships, and distribution establishment via MTA
- Commercial supply to pharmaceutical companies, CROs, and chemical manufacturers
Background and Technology
Traditional male reproductive toxicity testing relies on time- and labor-intensive animal sacrifices and post-mortem histopathology, creating a bottleneck in applying the 3Rs principles. Additionally, fluorescent reporter models like Acr-GFP suffer from poor tissue penetration, preventing continuous in vivo tracking of deep organs like the testes. To address these challenges, we developed a highly penetrative, quantitative bioluminescent mouse model (Acr-Luc KI) and a corresponding primary cell assay system. To ease colony management burdens for academia and satisfy strong industrial demand, we are seeking a global partnership with leading laboratory animal suppliers for deposition, breeding, and commercial distribution.
Principal Investigator
Hisanori Fukunaga (Graduate School of Health Science, Hokkaido University)
Patents and Publications
- Patent pending
- Information on related literature is included in the materials. Please click the “Iinterested in this technology? [Download Materials]” button below to download and view the materials.